Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00613782
Registration number
NCT00613782
Ethics application status
Date submitted
31/01/2008
Date registered
13/02/2008
Date last updated
1/07/2014
Titles & IDs
Public title
Reandron in Diabetic Men Witn Low Testosterone Level
Query!
Scientific title
Testosterone Replacement Therapy in Men With Type 2 Diabetes Mellitus and Low Testosterone Levels
Query!
Secondary ID [1]
0
0
Reandron 1000 (ZK 5488) 321399
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes
0
0
Query!
Hypogonadism
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Reandron 1000
Treatment: Drugs - placebo
Active Comparator: 1 - Reandron 100 treatment
Placebo Comparator: 2 - Placebo
Treatment: Drugs: Reandron 1000
1000mg at 0,6,18,30 weeks
Treatment: Drugs: placebo
placebo injection 0,6.18.30 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Insulin Resistance
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
40 weeks
Query!
Secondary outcome [1]
0
0
Bone microarchitecture
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
40 weeks
Query!
Eligibility
Key inclusion criteria
- Type 2 diabetes
- Testosterone less than 10 nmol/L
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Contraindication to
- Testosterone or
- IM injection
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2/Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
88
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Austin Health - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3084 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Austin Health
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
In men with type 2 diabetes, low testosterone levels have been associated with insulin
resistance, truncal obesity and symptoms such as fatigue and erectile dysfunction. Low
testosterone may impair cardiac function and increase cardiovascular risk and cause
osteoporosis. The goal of this project is to assess prospectively whether, in men with type 2
diabetes mellitus and low testosterone levels, testosterone replacement improves insulin
resistance, body composition, bone density, cardiac function symptoms associated with low
testosterone level.
The investigators will recruit 140 ambulatory men with type 2 diabetes and a low serum
testosterone level (<10 nmol/L) from Austin Health Endocrine clinics, General Practise
surgeries, and from the general public by direct consumer advertising via newspaper and other
local media. Men will be randomised to either intramuscular testosterone undecanoate
(Reandron 1000, Bayer Schering Pharma) or placebo. Men with contraindications to testosterone
replacement or to intramuscular injections will be excluded from the study. All men will
receive intramuscular testosterone or placebo injections at 0, 6, 18 and 30 weeks (a total of
four injections).
All 140 study subjects will have a clinical and laboratory assessment at baseline, 18 weeks
and at study end (40 weeks). All 140 subjects will also have imaging studies at baseline and
at study end (40 weeks). The study protocol is outlined in more detail below:
Clinical and laboratory assessment (Baseline and repeated 18 weeks, 40 weeks) A full medical
history and physical examination will be performed. Symptoms will be assessed by the
following standardised questionnaires: 1) Androgen Deficiency in the Aging Male (ADAM); 2)
Aging Male Symptom scale (AMS); 3) International Index of Erectile Dysfunction (IIED); 4)
International Prostate Symptom Score (IPSS); 5) SF-36 (all five questionnaires are attached
to Module 1).
Laboratory studies will consist of blood tests to measure total testosterone, fasting
glucose, C-peptide, HBA1c and other routine parameters.
Imaging studies (Baseline and repeated at 40 weeks)
1. Body composition and bone mineral density by DEXA
2. Body composition by magnetic resonance imaging
3. Bony micro-architecture by high resolution quantitative computed tomography [HR-pQCT]),
4. Cardiac dimensions and function by transthoracic doppler echocardiography
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00613782
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Mathis Grossmann
Query!
Address
0
0
Austin Health
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00613782
Download to PDF